Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Surfactant Bles versus Survanta in preterm neonates with respiratory distress syndrome
IRCT20210501051148N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of beractant in respiratory distress syndrome (RDS) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Mortality, Patent ductus arteriosus and 4 more. Started May 2021; status: completed.
02
Drugs
beractant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20210501051148N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210501051148N1.